undamentalytics Newsletter
Sign in

Aclaris Therapeutics, Inc. cash flow statement

In fiscal 2025, Aclaris Therapeutics, Inc.'s operations generated −$47.1m of cash; it spent $111,000 on capital projects, leaving free cash flow of −$47.2m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−55−101−96−39−52−68−78−20−47−62
Depreciation and amortisation0261111100
Stock-based pay14201611141521111212
Capital spending1120011000
Free cash flow−56−102−98−39−52−68−80−20−47−62
Free cash flow after stock pay−70−122−114−50−67−83−100−31−60−74

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ACRS vs COYAACRS vs APLMACRS vs ADAG

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aclaris Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aclaris Therapeutics, Inc.